Inactive Instrument

Intervacc AB Share Price Nasdaq Stockholm

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- ^SEK	-

20/08	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	Calendar Thursday, August 20	FW

Analysts' recommendations : Intervacc AB

20/24/20	Penser reiterates motivated value for Intervacc - report met expectations	FW
21/24/21	Penser lowers Intervacc's motivated value	FW
17/23/17	Penser makes minor estimate adjustments in Intervacc	FW
04/23/04	Penser lowers its motivated value for Intervacc to SEK 26-28 (48-54)	FW
20/23/20	Penser halves the motivated value for Intervacc - which falls on the stock exchange	FW

More recommendations

Managers and Directors : Intervacc AB

Manager	Title	Age	Since
Carl-Johan Dalsgaard CEO	Chief Executive Officer	70	05/02/2026
Jan Persson DFI	Director of Finance/CFO	-	06/02/2020
Andrew Waller CTO	Chief Tech/Sci/R&D Officer	-	11/06/2020

Director	Title	Age	Since
Emil Billbäck CHM	Chairman	56	13/05/2026
Carl Erik Mathias Uhlén BRD	Director/Board Member	72	01/01/2024
Björn Ingemar Odlander BRD	Director/Board Member	68	01/01/2025

More insiders

Intervacc AB is a Sweden-based biotechnology company. It develops vaccines based on recombinant proteins for animal health care. The Companyâ€™s candidate vaccine against strangles Strangvac consists of soluble recombinant proteins and devoids any living infectious agent. The Company operates through two subsidiaries: Nord Vacc Lakemedel AB and Mybac-Vettech AB. Nord Vacc Lakemedel AB markets and distributes veterinary vaccines, pharmaceuticals and vitamins on European market. It offers assortment of fur animal vaccines, the Febrivac range, as well as swine vaccines for Swedish and Danish markets. Mybac-Vettech AB is a technology platform that focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses.

Employees

Sector

Biotechnology & Medical Research

Calendar

12/11 Earnings release - Q3 2026

More about the company

All transcripts on over 9000 companies, on the day they post their earnings!

Unlock them now!

Market Cap	36Cr 3.83Cr 3.29Cr 3.08Cr 2.82Cr 5.31Cr 365.99Cr 5.33Cr 14Cr 184.45Cr 14Cr 14Cr 610.47Cr	P/E 2026 *	-0.96x	P/E 2027 *	-0.96x
Enterprise Value	28Cr 2.9Cr 2.49Cr 2.33Cr 2.13Cr 4.02Cr 276.67Cr 4.03Cr 11Cr 139.44Cr 11Cr 11Cr 461.48Cr	EV / Sales 2026 *	13.1x	EV / Sales 2027 *	10.1x
Free-Float	80.66%	Yield 2026 *	-	Yield 2027 *	-

20/08	Intervacc AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
20/08	Calendar Thursday, August 20	FW
31/07	Intervacc Submits Type Ii Variation Application to Ema Seeking 12-Month Duration of Immunity for Strangvac	CI
30/07	Intervacc Seeks EU Regulatory Approval to Extend Horse Vaccine's Immunity Duration	MT
29/07	Intervacc Gets Special Approval to Send Equine Vaccine to New Zealand	MT
29/07	Intervacc AB Publ Makes First Export Of Strangvac To New Zealand Under Special Circumstances Permit	CI
22/05	Intervacc AB Completes Successful Evaluation of Us Strain of Strangles Pathogen Ahead of Clinical Trials	CI
15/05	Sweden's Intervacc Elects New Chair	MT
15/05	Appoints Emil Billbäck as chairman	RE
13/05	Intervacc elects Emil Billbäck as chairperson of board	RE
13/05	Intervacc AB Announces Board Changes	CI
13/05	Intervacc Q1 net sales down at SEK 3.4 million	RE
13/05	Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

24/08	Intervacc (Q2 Review): Key catalysts nearing	AQ
21/08	Intervacc: In the right direction – Q2 review	AQ
20/08	Intervacc (Q2 initial take): Few surprises – all eyes on the label extension	AQ
30/07	Intervacc submits Type II variation to EMA seeking 12-month duration of immunity for Strangvac	AQ
29/07	Intervacc: New Zealand order validates Strangvac’s position	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	+3.31%	-3.70%	+61.03%	+103.64%	7.06TCr
ARGENX SE	-0.24%	+0.31%	+50.15%	+92.67%	6.61TCr
BIONTECH SE	-1.03%	+0.46%	+8.14%	-5.28%	2.8TCr
INSMED INCORPORATED	-2.41%	-2.95%	-9.77%	+455.82%	2.65TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.30%	-0.69%	+63.18%	+11.93%	2.64TCr
PHARMAESSENTIA CORPORATION	+1.02%	+6.43%	+269.42%	+420.34%	2.04TCr
GENMAB A/S	+0.18%	+0.93%	+34.64%	-17.45%	2.02TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.91%	-4.37%	+13.33%	+531.29%	1.6TCr
EXELIXIS, INC.	-1.50%	+2.92%	+43.50%	+151.30%	1.37TCr
Average	-0.26%	+0.99%	+59.29%	+193.81%	3.2TCr
Weighted average by Cap.	+0.36%	+0.65%	+56.51%	+154.52%

	2026 *	2027 *
Net sales	2.11Cr 22.17L 19.03L 17.82L 16.32L 30.74L 21Cr 30.82L 82.48L 11Cr 83.25L 81.45L 35Cr	3Cr 31.58L 27.11L 25.38L 23.24L 43.77L 30Cr 43.9L 1.17Cr 15Cr 1.19Cr 1.16Cr 50Cr
Net income	-8.24Cr -86.64L -74.37L -69.63L -63.76L -1.2Cr -83Cr -1.2Cr -3.22Cr -42Cr -3.25Cr -3.18Cr -138.02Cr	-8.36Cr -87.9L -75.45L -70.64L -64.69L -1.22Cr -84Cr -1.22Cr -3.27Cr -42Cr -3.3Cr -3.23Cr -140.03Cr
Net Debt	-8.9Cr -93.52L -80.28L -75.16L -68.82L -1.3Cr -89Cr -1.3Cr -3.48Cr -45Cr -3.51Cr -3.44Cr -148.99Cr	-6.1Cr -64.1L -55.02L -51.51L -47.17L -88.86L -61Cr -89.11L -2.38Cr -31Cr -2.41Cr -2.35Cr -102.12Cr

Intervacc AB Share Price Nasdaq Stockholm

Stocks

Biotechnology & Medical Research

Valuation : Intervacc AB

Latest news : Intervacc AB

Analysts' recommendations : Intervacc AB

Press Releases : Intervacc AB

Managers and Directors : Intervacc AB

Bio Therapeutic Drugs

Financials

Company Profile